-
1.发明授权公开(公告)号：US12048761B2
公开(公告)日：2024-07-30
申请号：US15765854
申请日：2016-10-12
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DESCARTES , UNIVERSITÉ PARIS DIDEROT—PARIS 7 , FONDATION ASILE DES AVEUGLES , SORBONNE UNIVERSITÉ
IPC分类号： A61K31/437 , A61K9/00 , A61K31/4409 , A61K31/551 , A61P27/02
CPC分类号： A61K9/0051 , A61K9/0048 , A61K31/437 , A61K31/4409 , A61K31/551 , A61P27/02
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion. In particular, the present invention relates to a method of treating retinal capillary non-perfusion in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a ROCK inhibitor.
-
2.发明授权公开(公告)号：US11559513B2
公开(公告)日：2023-01-24
申请号：US16846611
申请日：2020-04-13
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITÉ PARIS DIDEROT—PARIS 7
IPC分类号： A61K31/403
摘要： The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.
-
公开(公告)号：US11383004B2
公开(公告)日：2022-07-12
申请号：US16371235
申请日：2019-04-01
申请人： INSERM (Institut de la Santé et de la Recherche Médicale) , Université Paris Diderot—Paris 7 , Centre National de la Recherche Scientifique (CNRS) , Université Paris XIII Paris-Nord , École Supérieur de Physique et de Chimie Industrielles de Paris
摘要： The present invention relates to methods for adhering tissue surfaces and materials and biomedical uses thereof. In particular the present invention relates to a method for adhering a first tissue surface to a second tissue surface in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on at least one of the tissue surfaces, and approximating the surfaces for a time sufficient for allowing the surfaces to adhere to each other. The present invention also relates to a method for adhering a material to a biological tissue in a subject in need thereof, comprising the steps of adsorbing a layer of nanoparticles on the surface of the material and/or the biological tissue and approximating the material and the biological tissue for a time sufficient for allowing the material and the biological tissue to adhere to each other.
-
公开(公告)号：US20210347890A1
公开(公告)日：2021-11-11
申请号：US17305966
申请日：2021-07-19
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , UNIVERSITE PARIS 13 - PARIS NORD , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS , INSTITUT PASTEUR , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
摘要： Disclosed is CD31shed for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31shed ligand in different rat models of inflammation indeed showed that CD31shed is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31shed present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31shed ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
-
公开(公告)号：US10924687B2
公开(公告)日：2021-02-16
申请号：US16478404
申请日：2017-12-22
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , SORBONNE UNIVERSITÉ , Université Paris Diderot—Paris 7 DIDEROT VALORISATION , ECOLE NORMALE SUPERIEURE DE PARIS , UNIVERSITÉ DE BOURGOGNE
摘要： High dynamic range (HDR) images are generated on the basis of a plurality of images obtained by non-destructive reading of an image sensor, called NDRO images. An HDR image generation method includes: the determination of a criterion of desired quality for the HDR image; at least two non-destructive readings of the sensor delivering at least two successive NDRO images; the selection, as a function of the criterion of desired quality, of the first and of the last NDRO image to be used to generate the HDR image; the generation of the HDR image on the basis of information extracted from a series of successive NDRO images starting with the first and terminating with the last NDRO image to be used; the storage of a single image at one and the same time throughout the entire HDR generation phase.
-
6.发明申请公开(公告)号：US20200087403A1
公开(公告)日：2020-03-19
申请号：US16493901
申请日：2018-03-14
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE BORDEAUX , CHU HÔPITAUX DE BORDEAUX , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , UNIVERSITÉ PARIS XIII PARIS-NORD
发明人： Chloé JAMES , Thierry COUFFINHAL , Virginie GOURDOU-LATYSZENOK , Alexandre GUY , Martine JANDROT-PERRUS
IPC分类号： C07K16/28 , C12N15/113 , A61K31/17 , A61P7/02
摘要： Thrombosis is the main cause of morbidity and mortality in patients with JAK2V617F positive myeloproliferative neo-plasms (MPN). Recent works reported the presence of JAK2V617F in endothelial cells in some MPN patients. Here, the inventors show that JAK2V617F endothelial cells promote thrombosis through induction of endothelial P-selectin expression and thus demonstrate that P-selectin blockade was sufficient to reduce the increased propensity of thrombosis. Accordingly the present invention relates to a method of treating thrombosis in a patient suffering from a myeloproliferative neoplasm comprising administering to the patient a therapeutically effective amount of a P-selectin antagonist.
-
公开(公告)号：US10313018B2
公开(公告)日：2019-06-04
申请号：US15547830
申请日：2016-02-04
申请人： PARIS SCIENCES ET LETTRES—QUARTIER LATIN , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS , UNIVERSITÉ PARIS DIDEROT—PARIS 7
发明人： Sylvain Gigan , Florent Krzakala , Laurent Daudet , Igor Carron , Angélique Dremeau , Alaa Saade
摘要： The invention is related to a digital-data mixing apparatus (2), a data processing system (1) and an associated method for mixing digital-data. The digital-data mixing apparatus comprises, integrated in a housing (7), input means (8) for receiving a plurality of bits (I1 . . . In) of input digital data (4), electromagnetic emission means (9) for generating a modulated electromagnetic beam (15) wherein said input digital data (4) are converted in simultaneous modulations of the modulated electromagnetic beam (15), electromagnetic scattering means (10) for scattering the modulated electromagnetic beam (15) in a scattered electromagnetic beam (19), receiving means (11) for converting the scattered electromagnetic beam (19) in bits (O1 . . . Om) of output digital data (5), and output means (12) for providing said output digital data (5).
-
公开(公告)号：US20180214550A1
公开(公告)日：2018-08-02
申请号：US15741944
申请日：2016-07-07
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , INSTITUT JEAN GODINOT
发明人： Armand BENSUSSAN , Martine BAGOT , Jérôme GIUSTINIANI , Yacine MERROUCHE , Adèle DE MASSON , Anne MARIE-CARDINE
IPC分类号： A61K39/395 , A61K39/39 , C07K16/28
CPC分类号： A61K39/39566 , A61K39/39 , A61K2039/505 , A61K2039/507 , A61K2039/572 , C07K16/2896 , C07K2317/31
摘要： The present disclosure relates to methods and pharmaceutical compositions for enhancing NK cell killing activities. In particular, the disclosure relates to a method of enhancing NK cell killing activities in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound capable of stimulating CD245 on NK cells.
-
9.发明申请公开(公告)号：US20180162911A1
公开(公告)日：2018-06-14
申请号：US15737358
申请日：2016-06-17
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DESCARTES , UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
IPC分类号： C07K14/00 , C07K7/08 , A61P13/12 , G01N33/564 , G01N33/68
CPC分类号： C07K14/00 , A61K38/00 , A61P13/12 , C07K7/08 , C07K2319/00 , C12N9/6424 , C12Y304/21047 , G01N33/564 , G01N33/6854
摘要： The present invention relates to polypeptides for the diagnosis and treatment of C3 NeF associated C3 Glomerulopathy. In particular, the present invention is defined by the claims. In particular, the present invention relates to a polypeptide that is capable of inhibiting the binding of C3 NeF to C3 convertase and which comprises a first segment which consists of n consecutive amino acids selected in a first amino acid sequence set forth in SEQ ID NO:1 fused to a second segment which consists of n′ consecutive amino acids selected in a second amino acid sequence set forth in SEQ ID NO:2, wherein n and n′ represent integer number, n and n′≥3 and n+n′≥10.
-
10.发明申请公开(公告)号：US20180021302A1
公开(公告)日：2018-01-25
申请号：US15549401
申请日：2016-02-12
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITÉ PARIS DIDEROT - PARIS 7
IPC分类号： A61K31/403
CPC分类号： A61K31/403 , A61K2300/00
摘要： The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.
-
-
-
-
-
-
-
-
-
搜索结果
86 条记录 (耗时 0.034 秒)
